AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...

AbbVie has filed a lawsuit challenging federal guidance on how “patient” is defined under the 340B program, according to an April 8 press release. The company said the current definition, based on ...

April 8 (Reuters) - AbbVie (ABBV.N), opens new tab has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount program. Under ‌the 340B program, ...

JPMorgan maintains its Overweight rating and $260 price target on AbbVie (ABBV), calling the pullback a buying opportunity as the firm sees upside to consensus estimates backed by strong Skyrizi and ...

Two more drug-making giants will officially start selling popular commercial medications on the White House's discounted pharmaceutical site as soon as Monday, CBS News exclusively learned. American ...

Ahead of Opening Day, Chicago-based pharmaceutical company AbbVie is expanding its relationship with Major League Baseball with its league-wide “Striking Out Cancer” initiative. The campaign that ...

AbbVie is swinging for the fences with a new partnership in support of cancer awareness and research. The pharma has teamed up with Major League Baseball as the league’s official pharmaceutical ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

AbbVie has unveiled the first data from its $350 million obesity bet, with the amylin analog demonstrating weight loss of close to 10% after 12 weeks in one dose cohort. Amylin emerged last year as ...

AbbVie had 10 therapies with sales of $1 billion or more each in 2025. The pharma giant has raised its dividends annually for 54 consecutive years. AbbVie has a large pipeline of mid- and late-stage ...

AbbVie has grown its dividend by more than 330% since it became a public company in 2013. It generates strong free cash flow, which leaves room for more rate hikes in the future. It also makes for a ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...